This paper was published through Galoá and has a deposited DOI. To cite this paper, use one of the standards below:
In case you are one of the co-authors and want to register this paper in your Lattes, use the following code: doi > 10.17648/cics-2025-216789
If you've NEVER registered a DOI in your Lattes, check our tutorial!INTRODUCTION: In contemporary diseases, synthetic drugs play essential roles in both prevention and cure. Exogenous farnesol has been used to treat allergic asthma, diabetes, atherosclerosis, obesity, and hyperlipidemia. Farnesol has been found to promote wound healing by suppressing the production of pro-inflammatory cytokines such as interleukin (IL)-1 beta, IL-6, and tumor necrosis factor TNFα. OBJECTIVE: This study aims to review the current evidence on the mechanisms of action of farnesol and its clinical perspectives. METHODS: This study is an integrative literature review, carried out in the PubMed, SciELO, and Elsevier databases, considering articles published between 2015 and 2025. Of the 31 articles initially identified, 6 met the inclusion criteria. An in silico analysis was performed with the PubChem and PreADMET programs. RESULTS AND DISCUSSION: The analyzed studies showed that farnesol has the potential to reduce the formation of Candida albicans biofilms, act as a protective agent against skin lesions induced by pollutants, modulate inflammatory and apoptotic processes in different experimental models, in addition to exerting cardioprotective and neuroprotective effects. It has also demonstrated the ability to prevent induced cardiac hypertrophy and improve demyelinating characteristics in Charcot-Marie-Tooth disease type 1A. FINAL CONSIDERATIONS: The results suggest that farnesol has broad therapeutic applicability, and may contribute to the development of new treatments in areas such as oncology, cardiology, neurology, and inflammatory diseases
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper